β2 Adrenoceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery

Jones, J. Mark; Petrofski, Jason A.; Wilson, Katrina H.; Steenbergen, Charles; Koch, Walter J.; Milano, Carmelo A.
December 2004
European Journal of Cardio-Thoracic Surgery;Dec2004, Vol. 26 Issue 6, p1161
Academic Journal
Abstract: Objective: Heart surgery is associated with impairment of the myocardial β-adrenoceptor (βAR) system. Effective therapies for post-operative ventricular dysfunction are limited. Prolonged inotrope exposure is associated with further βAR down-regulation. Left ventricular (LV) dysfunction and myocardial βAR impairment were assessed following cardiopulmonary bypass (CPB) and cardioplegic arrest in a pig model. Transfer of the human β2-adrenoceptor transgene (Adeno-β2AR) during cardioplegic arrest was then tested as a potential therapy. Methods: Five groups of six neonatal piglets were studied. One group did not undergo surgery (Group A). Adeno-β2AR or phosphate buffered saline (PBS) were delivered via the aortic root during cardioplegic arrest. Groups B (PBS) and C (Adeno-β2AR) were assessed at 2 days while Groups D (PBS) and E (Adeno-β2AR) were assessed at 2 weeks from the time of surgery. An LV micromanometer was inserted under sedation to obtain pressure recordings following surgery. βAR density was measured subsequently. Results: Following cardiac surgery LV βAR density was reduced (104±5.7 vs 135±6.1fmol/mg membrane protein; P=0.007), and, in response to β agonist stimulation, LV dP/dtmax was reduced (4337±405 vs 5328±194mmHg/s; P<0.05) compared to animals which did not undergo surgery. Adeno-β2AR therapy during cardiac surgery resulted in elevated LV βAR density (520±250.9fmol/mg) 2 days post-operatively compared to PBS (104±5.7fmol/mg; P=0.002) and compared to the no surgery group (135±6.1fmol/mg; P=0.002). Elevated LV βAR density was also present at 2 weeks (315±74.1 vs 119±7.1fmol/mg; P=0.002). In addition, Adeno-β2AR therapy enhanced β agonist stimulated LV dP/dtmax (5348±121 vs 4337±405mmHg/s; P<0.05) and heart rate (209±6.9 vs 173±11.0bpm; P<0.05), and reduced LVEDP (2.1±0.4 vs 6.4±1.8mmHg; P<0.05) compared to PBS treatment. Interestingly, gene delivery was cardiac-selective and beneficial effects on function persisted for 2 weeks. Moreover, β2AR gene transfer ameliorated LV dysfunction following surgery such that there were no significant differences between non-operated controls and animals treated with Adeno-β2AR during CPB and cardioplegic arrest. Conclusions: Reduced βAR density and impaired LV function were present following CPB and cardioplegic arrest. Cardiac-selective β2AR gene transfer during CPB resulted in amelioration of LV dysfunction after cardiac surgery. Such a technique may offer a new approach to post-operative ventricular support.


Related Articles

  • Suppression of Nonsense Mutations in the Dystrophin Gene by a Suppressor tRNA Gene. Kiselev, A. V.; Ostapenko, O. V.; Rogozhkina, E. V.; Kholod, N. S.; Seit-Nebi, A. S.; Baranov, A. N.; Lesina, E. A.; Ivashchenko, T. E.; Sabetskii, V. A.; Shavlovskii, M. M.; Rechinsky, V. O.; Kisselev, L. L.; Baranov, V. S. // Molecular Biology;Jan2002, Vol. 36 Issue 1, p30 

    Nonsense mutations in the dystrophin gene are the cause of Duchenne muscular dystrophy (DMD) in 10–15% of patients. In such an event, one approach to gene therapy for DMD is the use of suppressor tRNAs to overcome the premature termination of translation of the mutant mRNA. We have...

  • Human gene therapy. Anderson, W. French // Nature;5/1/1998, Vol. 392 Issue 6679, p25 

    Discusses human gene therapy as a treatment for disease as of May 1998. Vectors based on RNA viruses and DNA viruses; Other DNA virus-based vectors; Non-viral vectors; Clinical studies; Ethical issues; The future; The problem of the development of safe and efficient gene-delivery systems.

  • Subject Index to Volume 4. Bentham Science Publishers // Current Gene Therapy;Feb2005, Vol. 5 Issue 1, p145 

    Presents the subject index of the February 2005 issue of the periodical "Current Gene Therapy."

  • Author Index to Volume 4. Bentham Science Publishers // Current Gene Therapy;Feb2005, Vol. 5 Issue 1, p143 

    Presents the author index of the February 2005 issue of the periodical "Current Gene Therapy."

  • Better health through gene theraphy. Grace, Eric S. // Futurist;Jan/Feb98, Vol. 32 Issue 1, p39 

    Explains the concept of gene therapy. Plan of the Human Genome Project to map and sequence the genes found in human deoxyribonucleic acid (DNA); Criticism that the project is simply unnecessary and tedious; Advantage of using genetic engineering in producing drugs. INSETS: The importance of...

  • Legal worries accompany genetic breakthroughs. Goldberg, David J. // Dermatology Times;Feb2001, Vol. 22 Issue 2, p9 

    Cites legal impediments to genetic technology designed for medical use. Importance of developing safeguards to prevent abuse of genetic technology; Impact of the availability of information on genetically linked diseases to patient confidentiality; Possible public resistance to genetic testing...

  • Editorial. Martin, P.A. // Gene Therapy;Sep97, Vol. 4 Issue 9, p881 

    Discusses a survey of the development of gene therapy in Europe and the U.S. Barriers to the process of converting today's science into tomorrow's technology; Countries that are best placed to reap the rewards of gene therapy research; Comparative analysis of the innovation process in Great...

  • For Gene Therapy, Now-Quantified Risks Are Deemed Troubling. Twombly, Renee // JNCI: Journal of the National Cancer Institute;7/16/2003, Vol. 95 Issue 14, p1032 

    Examines several studies demonstrating the accomplishments and risks of gene therapy. Children with X-linked severe combined immunodeficiency disorder who developed leukemia after receiving treatment with gene therapy; Tendency of the murine leukemia virus to insert genes into transcription...

  • News and comments.  // Gene Therapy;Feb98, Vol. 5 Issue 2, p145 

    Presents updates relevant to gene therapy for February 1998. Optimism for the increased number of gene therapy techniques in 1998; Expectations of more investments for gene therapy companies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics